Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

USDA database

This article was originally published in The Tan Sheet

Executive Summary

The Department of Agriculture releases measures of antioxidant capacities for 277 selected foods on Nov. 6. The new database provides "easy access to antioxidant values for a wide variety of foods, many of which may be excellent sources of healthful compounds," USDA says. In September, industry group executives said the database being developed by the Department of Agriculture to track consumers' dietary supplement intake could "help firms with information they need for product development," (1"The Tan Sheet" Sept. 3, 2007, p. 17). "The database will be used by scientists to help guide ongoing research into how antioxidants may correlate to health benefits," USDA says...

You may also be interested in...



USDA Supplement Ingredient Database Greeted As Effective Tool For Firms

Industry group executives say a database the Department of Agriculture is developing to track consumers' dietary supplement intake could help firms with information they need for product development

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS101097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel